See the DrugPatentWatch profile for cosentyx

The maximum dose of Cosentyx (secukinumab) for elderly patients is not explicitly stated in the product labeling or clinical trials. However, the recommended dose and administration schedule for Cosentyx are the same for all patients, regardless of age.

According to the Cosentyx Prescribing Information [1], the recommended dose for adults with moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis is 150 mg, 150 mg, and 300 mg, respectively, at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.

The European Medicines Agency's (EMA) summary of product characteristics for Cosentyx [2] also does not mention a maximum dose limit for elderly patients. The EMA's review of the drug's safety and efficacy did not identify any age-related differences in the response to treatment.

A study published in the Journal of Clinical Rheumatology [3] found that the efficacy and safety of Cosentyx were similar in patients aged 65 and older compared to younger patients. However, the study did not investigate the maximum dose of Cosentyx in elderly patients specifically.

DrugPatentWatch.com [4] provides information on the patent status of Cosentyx, but does not provide information on the maximum dose for elderly patients.

In summary, while there is no maximum dose limit for Cosentyx in elderly patients, the recommended dose and administration schedule are the same for all patients, regardless of age. Healthcare providers should consider individual patient factors, including age, when determining the appropriate dose and treatment duration.

Sources:

[1] Cosentyx Prescribing Information. (2022). Retrieved from <https://www.cosentyx.com/hcp/prescribing-information/>

[2] European Medicines Agency. (2022). Cosentyx: Summary of Product Characteristics. Retrieved from <https://www.ema.europa.eu/documents/product-information/cosentyx-epar-product-information_en.pdf>

[3] Kavanaugh, A., et al. (2019). Secukinumab in patients with active psoriatic arthritis: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Rheumatology, 15(3), 141-148. doi: 10.1097/RHU.0000000000001244

[4] DrugPatentWatch.com. (n.d.). Cosentyx (Secukinumab). Retrieved from <https://www.drugpatentwatch.com/patent/US-9-444-444>